Skip to main content

Eurofins Genomics Buys VBC-Biotech Businesses, Establishes Austrian Subsidiary

NEW YORK (GenomeWeb) – Eurofins Genomics today announced the acquisition of VBC-Biotech's oligonucleotide synthesis and DNA sequencing businesses and the establishment of an Austrian subsidiary.

Eurofins Genomics is the genomics division of the Eurofins Scientific Group. The Austrian subsidiary, called Eurofins Genomics AT and headquartered in Vienna, will leverage Eurofins' global network, production capacity, and infrastructure.

"The new direct presence in Austria will provide value to our customers by demonstration our commitment to this market," Eurofins Genomics AT Managing Director Siegfried Schnabl said in a statement. "Furthermore, Vienna will serve as a perfect hub for future business into Central and Eastern Europe and beyond."

Financial and other terms of the deal were not disclosed.

Earlier this month, Eurofins Genomics established a subsidiary in Milan, Italy by buying the oligonucleotide and DNA sequencing business of Primm.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.